SUPPLEMENTARY MATERIAL

Supplemental Text. Description of Blinded Rescue

Patients in SELECT-COMPARE were rescued at weeks 14, 18, or 22 if they did not achieve ≥20% improvement from baseline in both tender and swollen joint count based on 68 or 66 joints, or at week 26 if they did not achieve low disease activity based on a Clinical Disease Activity Index (CDAI) score of ≤10. All switches were fully blinded, i.e. investigators, study patients, and the study team remained blinded to the treatment assignments both prior to and following switch.

An interactive response technology (IRT) system was used to randomize patients at baseline and to manage the rescue and switch protocol in a blinded manner. At weeks 14, 18, 22, and 26 a “yes” or “no” response was generated by the IRT system regarding patient rescue based on information (i.e., tender and swollen joint counts) entered by the study site. At week 26, if low disease activity based on CDAI was not met a patient was switched to the other or started on blinded study drug as rescue treatment (including those originally on placebo). Each patient was only rescued once.

Fleischmann RM, *et al. Ann Rheum Dis* 2020;0:1–8. doi: 10.1136/annrheumdis-2020-218412

Supplemental Figure S1. SELECT-COMPARE Study Design



ADA, adalimumab; BL, baseline; CDAI, Clinical Disease Activity Index; EOW, every other week; LDA, low disease activity; QD, once daily; PBO, placebo; SJC, swollen joint count; TJC, tender joint count; UPA, upadacitinib

[a]All PBO patients not rescued at W14, 18, or 22 were switched to UPA 15 mg at W26 regardless of their response. Each patient could only be rescued once, and switch was immediate and without washout.

Supplemental Figure S2. Change from Original Baseline in ACR response components HAQ-DI, TJC68, SJC66, PtGA, PhGA, Patient Assessment of Pain, and hsCRP for Non-responders [A] and Incomplete-responders [B]



S denotes time of switch
ADA, adalimumab; HAQ-DI, Health Assessment Questionnaire Disability Index; hsCRP, high sensitivity C-reactive protein; PhGA, physician global assessment; PtGA, patient global assessment; SJC66, swollen joint count based on 66 joints; TJC68, tender joint count based on 68 joints; UPA, upadacitinib

Supplemental Table S1. Patient Demographics and Disease Characteristics at Baseline and Switch

Mean (SD)[a]	UPA Switch to ADA				ADA Switch to UPA			
	Non-responders (n = 126) Rescued at W14/18/22 based on TJC68/SJC66		**Incomplete-responders (n = 126)** Rescued at W26 based on CDAI LDA		**Non-responders (n = 77)** Rescued at W14/18/22 based on TJC68/SJC66		**Incomplete-responders (n = 82)** Rescued at W26 based on CDAI LDA	
Age, years	54.4 (11.4)		55.0 (11.9)		54.6 (10.7)		53.3 (10.6)	
Female, No. (%)	103 (81.7)		108 (85.7)		63 (81.8)		70 (85.4)	
Duration of RA, years	9.0 (8.2)		7.0 (6.5)		10.0 (10.3)		6.4 (5.9)	
RF and/or ACPA positive, No. (%)	102 (81.0)		107 (84.9)		64 (83.1)		72 (87.8)	
Mean (SD)	**Baseline**	**Switch[b]**	**Baseline**	**Switch[b]**	**Baseline**	**Switch[b]**	**Baseline**	**Switch[b]**
CDAI	40.7 (13.3)	31.1 (15.1)	44.9 (12.9)	17.1 (7.1)	37.6 (12.0)	30.9 (13.8)	44.6 (13.9)	18.5 (9.4)
DAS28(CRP)	5.9 (1.0)	4.8 (1.3)	6.1 (0.9)	3.8 (0.7)	5.8 (1.0)	4.9 (1.2)	6.2 (0.9)	4.1 (0.9)
TJC68	29.9 (17.1)	24.8 (16.7)	31.1 (15.2)	10.1 (8.3)	26.4 (15.32)	24.5 (15.9)	29.7 (16.4)	10.8 (9.5)
SJC66	16.5 (10.5)	14.2 (11.4)	19.2 (11.3)	5.5 (7.1)	15.3 (8.3)	11.5 (8.2)	19.0 (11.2)	5.2 (5.5)
CRP, mg/L	19.4 (24.8)	7.6 (15.1)	19.8 (24.5)	6.6 (18.2)	21.2 (23.5)	11.1 (14.0)	24.0 (25.5)	10.7 (14.8)
Pt pain, mm	66.8 (19.5)	49.2 (24.8)	72.2 (18.0)	42.9 (23.3)	68.6 (18.0)	50.3 (23.4)	69.9 (16.9)	44.1 (22.9)
HAQ-DI	1.7 (0.6)	1.4 (0.7)	1.8 (0.5)	1.2 (0.6)	1.7 (0.6)	1.3 (0.6)	1.8 (0.5)	1.3 (0.5)
PtGA	63.7 (22.8)	48.2 (24.5)	69.7 (18.2)	43.2 (22.8)	68.0 (20.9)	51.2 (23.7)	70.4 (17.1)	45.0 (22.8)
PhGA	64.6 (16.4)	43.4 (23.4)	70.2 (16.0)	30.6 (17.4)	65.0 (18.0)	45.1 (22.4)	70.9 (16.0)	30.7 (19.0)

Abbreviations: ACPA, anti-citrullinated protein antibody; ADA, adalimumab; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PhGA, Physician's Global Disease Activity; PtGA, Patient's Assessment of Global Disease Activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC66, swollen joint count based on 66 joints; TJC68, tender joint count based on 68 joints; UPA, upadacitinib.

[a] Values are mean (SD) unless otherwise specified.
[b] Disease characteristics at time of switch.

Supplemental Table S2. Disease Activity Measures 6 Months Post Switch for All Incomplete-Responders and Excluding Incomplete-Responders Who Were Rescued Despite Achieving CDAI LDA

	UPA Switch to ADA		ADA Switch to UPA	
% (n/N)	**All Incomplete-Responders**	**Excluding Pts (n = 9) Who Were Inadvertently Rescued at W26**	**All Incomplete-Responders**	**Excluding Pts (n = 5) Who Were Inadvertently Rescued at W26**
ACR20	77.3 (92/119)	74.6 (85/114)	86.7 (65/75)	73.7 (56/76)
ACR50	46.7 (56/120)	45.9 (51/111)	62.53 (45/72)	63.2 (43/68)
ACR70	18.5 (22/119)	17.1 (19/111)	39.2 (29/74)	41.4 (29/70)
DAS28(CRP) ≤3.2	43.8 (53/121)	42.9 (48/112)	57.1 (44/77)	54.2 (39/72)
DAS28(CRP) <2.6	23.1 (28/121)	22.3 (25/112)	37.78 (29/77)	36.1 (26/72)
CDAI LDA	45.0 (54/120)	43.2 (48/111)	57.9 (44/76)	56.3 (40/71)
CDAI Remission	5.0 (6/120)	3.6 (4/111)	15.8 (12/76)	15.5 (11/71)
Mean Change from Baseline:				
HAQ-DI	-0.6	-0.6	-0.8	-0.8
TJC68	-23.8	-20.4	-24.3	-19.4
SJC66	-15.3	-13.6	-16.5	-14.0
PtGA	-32.2	-33.2	-40.6	-40.8
PhGA	-43.5	-43.0	-52.2	-52.3
Pt Pain	-34.4	-34.9	-41.0	-40.9
hsCRP	-11.3	-11.0	-18.2	-17.1

Abbreviations: ACR20/50/70, American College of Rheumatology response criteria; ADA, adalimumab; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C-reactive protein; LDA, low disease activity; PhGA, Physician's Global Disease Activity; PtGA, Patient's Assessment of Global Disease Activity; SJC66, swollen joint count based on 66 joints; TJC68, tender joint count based on 68 joints; UPA, upadacitinib.

Data reported as observed.

Supplemental Table S3. Demographics and Baseline Disease Characteristics of Patients Categorized as Double Non-responders (Based on CDAI) and Non-Double Non-responders

Mean (SD)[a]	Double Non-responder (n = 210)	Non-Double Non-responder[a] (n = 768)	Spearman Correlation Coefficient
Age, years	54.7 (11.1)	53.9 (12.2)	-0.003
Duration of RA diagnosis, years	8.2 (8.3)	8.2 (7.9)	-0.010
RF and/or ACPA positive, No. (%)	176 (83.8)	678 (88.3)	-0.060
CDAI	44.1 (12.7)	38.5 (12.8)	0.176
DAS28(CRP)	6.2 (0.9)	5.7 (1.0)	0.185
TJC68	31.9 (16.4)	24.9 (14.4)	0.184
SJC66	18.9 (11.0)	15.8 (9.5)	0.134
CRP, mg/L	22.1 (27.4)	17.6 (20.4)	0.051
Pt pain, mm	69.6 (15.3)	64.3 (17.6)	0.131
HAQ-DI	1.8 (0.5)	1.6 (0.6)	0.144
PtGA	70.4 (18.3)	63.2 (22.2)	0.130
PhGA	69.6 (15.3)	64.3 (17.6)	0.124

Abbreviations: ACPA, anti-citrullinated protein antibody; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PhGA, Physician's Global Disease Activity; PtGA, Patient's Assessment of Global Disease Activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC66, swollen joint count based on 66 joints; TJC68, tender joint count based on 68 joints.

[a] Values are mean (SD) unless otherwise specified.
[b] Non-double non-responder group includes patients who were rescued at any time point and responded to the second treatment, and patients who never switched.

Supplemental Table S4. Univariate Logistic Regression of Double Non-response with Baseline Characteristics

Parameter[a]	N	Odds Ratio (95% CI)	C (concordance) Index (95% CI)
Age, years	978	1.006 (0.993, 1.019)	0.528 (0.485, 0.570)
Duration of RA diagnosis, years	978	1.001 (0.982, 1.020)	0.493 (0.488, 0.538)
RF and/or ACPA positive	978	0.687 (0.448, 1.054)	0.522 (0.495, 0.550)
CDAI (0-76)	921	1.033 (1.020, 1.046)	0.623 (0.580, 0.667)
DAS28(CRP) (0.96-9.4[b])	972	1.647 (1.389, 1.952)	0.630 (0.588, 0.672)
TJC68 (0-68)	978	1.029 (1.019, 1.039)	0.630 (0.587, 0.673)
SJC66 (0-66)	978	1.029 (1.014, 1.044)	0.594 (0.551, 0.638)
CRP, mg/L	978	1.008 (1.002, 1.014)	0.536 (0.491, 0.581)
Pt pain (0-100 mm VAS)	978	1.018 (1.010, 1.026)	0.592 (0.551, 0.633)
HAQ-DI (0-3)	971	1.864 (1.424, 2.439)	0.601 (0.559, 0.643)
PtGA (0-100 mm VAS)	921	1.019 (1.009, 1.029)	0.587 (0.544, 0.630)
PhGA (0-100 mm VAS)	972	1.017 (1.009, 1.025)	0.592 (0.550, 0.634)

Abbreviations: ACPA, anti-citrullinated protein antibody; CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PhGA, Physician's Global Disease Activity; PtGA, Patient's Assessment of Global Disease Activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SJC66, swollen joint count based on 66 joints; TJC68, tender joint count based on 68 joints; VAS, visual analogue scale.

[a] Parameter evaluated at baseline. Parameter scale and/or ranges are provided in parentheses, when applicable, to aid the interpretation of the odds ratio.
[b] Max of 9.4 if CRP is 100 mg/L[1]

Supplemental Table S5. Number and Percentage of Patients Experiencing TEAEs 0-3 Months and 4-6 Months Post Treatment Switch and While on Continuous Therapy

	0-3 Months[a]				4-6 Months[a]			
Adverse Events No. (%) [95% CI]	**UPA 15 mg to ADA (n = 252)**	**Continuous ADA (n = 168)**	**ADA to UPA 15 mg (n = 159)**	**Continuous UPA (n = 398)**	**UPA 15 mg to ADA (n = 252)**	**Continuous ADA (n = 168)**	**ADA to UPA 15 mg (n = 159)**	**Continuous UPA (n = 398)**
Any AE	125 (49.6) [43.5, 55.7]	86 (51.2) [43.7, 58.6]	64 (40.3) [33.0, 48.0]	193 (48.5) [43.6, 53.4]	90 (35.7) [30.1, 41.8]	63 (37.5) [30.5, 45.0]	58 (36.5) [29.4, 44.2]	168 (42.2) [37.5, 47.1]
Serious AE	6 (2.4) [1.1, 5.1]	9 (2.3) [2.0, 8.4]	6 (3.8) [1.7, 8.0]	9 (2.3) [1.2, 4.2]	11 (4.4) [2.5, 7.7]	5 (3.0) [1.3, 6.8]	9 (5.7) [3.0, 10.4]	5 (1.3) [0.5, 2.9]
AE leading to D/C	7 (2.8) [1.4, 5.6]	18 (4.5) [6.0, 14.9]	3 (1.9) [0.6, 5.4]	18 (4.5) [2.9, 7.0]	8 (3.2) [1.6, 6.1]	5 (3.0) [1.3, 6.8]	5 (3.1) [1.4, 7.3]	4 (1.0) [0.4. 2.6]
Deaths	0 [0.0, 1.5]	0 [0.1, 3.3]	0 [0.0, 2.4]	0 [0.0, 1.0]	0 [0.0, 1.5]	1 (0.6) [0.1, 3.3]	0 [0.0, 2.4]	0 [0.0, 1.0]
Infection	41 (16.3) [12.3, 21.3]	40 (23.8) [18.0, 30.8]	30 (18.9) [13.6, 25.7]	100 (25.1) [21.1, 29.6]	46 (18.3) [14.0, 23.5]	32 (19.0) [13.8, 25.7]	29 (18.2) [13.0, 25.0]	89 (22.4) [18.5, 26.7]
Serious infection	2 (0.8) [0.2, 2.9]	3 (1.8) [0.6, 5.1]	4 (2.5) [1.0, 6.3]	6 (1.5) [0.7, 3.3]	3 (1.2) [0.4, 3.4]	1 (0.6) [0.1, 3.3]	2 (1.3) [0.4, 4.5]	1 (0.3) [0.0, 1.4]
Opportunistic infection	0 [0.0, 1.5]	1 (0.6) [0.1, 3.3]	1 (0.6) [0.1, 3.5]	2 (0.5) [0.1, 1.8]	0 [0.0, 1.5]	0 [0.0, 2.2]	1 (0.6) [0.1, 3.5]	0 [0.0, 1.0]
Herpes zoster	1 (0.4) [0.1, 2.2]	1 (0.6) [0.1, 3.3]	2 (1.3) [0.4, 4.5]	3 (0.8) [0.3, 2.2]	2 (0.8) [0.2, 2.9]	0 [0.0, 2.2]	2 (1.3) [0.4, 4.5]	0 [0.0, 1.0]
TB	0 [0.0, 1.5]	0 [0.0, 2.2]	0 [0.0, 2.4]	0 [0.0, 1.0]	7 (2.8) [1.4, 5.6]	0 [0.0, 2.2]	3 (1.9) [0.6, 5.4]	1 (0.3) [0.0, 1.4]
Malignancy (excl. NMSC)	0 [0.0, 1.5]	0 [0.0, 2.2]	1 (0.6) [0.1, 3.5]	0 [0.0, 1.0]	1 (0.4) [0.1, 2.2]	0 [0.0, 2.2]	0 [0.0, 2.4]	0 [0.0, 1.0]
NMSC	0 [0.0, 1.5]	1 (0.6) [0.1, 3.3]	0 [0.0, 1.0]	0 [0.0, 1.0]	0 [0.0, 1.5]	0 [0.0, 2.2]	0 [0.0, 2.4]	0 [0.0, 1.0]
GI perforation[b]	0 [0.0, 1.5]	0 [0.0, 2.2]	0 [0.0, 2.4]	2 (0.5) [0.1, 1.8]	0 [0.0, 1.5]	0 [0.0, 2.2]	1 (0.6) [0.1, 3.5]	0 [0.0, 1.0]
Adjudicated MACE	0 [0.0, 1.5]	0 [0.0, 2.2]	0 [0.0, 2.4]	0 [0.0, 1.0]	0 [0.0, 1.5]	2 (1.2) [0.3, 4.2]	0 [0.0, 2.4]	0 [0.0, 1.0]
Adjudicated VTE	0 [0.0, 1.5]	2 (1.2) [0.3, 4.2]	0 [0.0, 2.4]	0 [0.0, 1.0]	0 [0.0, 1.5]	1 (0.6) [0.1, 3.3]	1 (0.6) [0.1, 3.5]	0 [0.0, 1.0]
Hepatic disorder	8 (3.2) [1.6, 6.1]	6 (3.6) [1.7, 7.6]	4 (2.5) [1.0, 6.3]	22 (5.5) [3.7, 8.2]	8 (3.2) [1.6, 6.14	2 (1.2) [0.3, 4.2]	2 (1.3) [0.4, 4.5]	11 (2.8) [1.6, 4.9]
Anemia	3 (1.2) [0.4, 3.4]	2 (1.2) [0.3, 4.2]	2 (1.3) [0.4, 4.5]	6 (1.5) [0.7, 3.3]	1 (0.4) [0.1, 2.2]	0 [0.0, 2.2]	2 (1.3) [0.4, 4.5]	1 (0.3) [0.0, 1.4]
Neutropenia	4 (1.6) [0.6, 4.0]	0 [0.0, 2.2]	2 (1.3) [0.4, 4.5]	7 (1.8) [0.9, 3.6]	2 (0.8) [0.2, 2.9]	2 (1.2) [0.3, 4.2]	1 (0.6) [0.1, 3.5]	6 (1.5) [0.7, 3.4]
Lymphopenia	1 (0.4) [0.1, 2.2]	0 [0.0, 2.2]	1 (0.6) [0.1, 3.5]	8 (2.0) [1.0, 3.9]	1 (0.4) [0.1, 2.2]	0 [0.0, 2.2]	0 [0.0, 2.4]	2 (0.5) [0.1, 1.8]
CPK elevation	2 (0.8) [0.2, 2.9]	1 (0.6) [0.1, 3.3]	0 [0.0, 2.3]	7 (1.8) [0.9, 3.6]	1 (0.4) [0.1, 2.2]	1 (0.6) [0.1, 3.3]	1 (0.6) [0.1, 3.5]	4 (1.0) [0.4, 2.6]

Abbreviations: ADA, adalimumab; AE, adverse event; CI, confidence interval; CPK, creatine phosphokinase; D/C, discontinuation; GI, gastrointestinal; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancer; TB, tuberculosis; TEAE, treatment-emergent adverse events; UPA, upadacitinib; VTE, venous thromboembolism.

[a] Data for switch groups are 0-3 and 4-6 months post switch. Data for continuous groups are from non-switchers and matching time periods starting at original randomization (months 0-3 and 4-6 of continuous therapy).

[b] Gastrointestinal perforations were identified through Standardized Medical Dictionary for Regulatory Activities query.

Values are the number (%) of patients with events. Confidence intervals are calculated using the Wilson method.

Supplemental Table S6. Data Points Plotted in Figure 2

	Weeks Post Switch					
Parameter, n/N (%)	0	4	8	12	18	24
A. Non-responders						
ACR20						
Switch to UPA	3/77 (3.9)	43/75 (57.3)	49/74 (66.2)	49/75 (65.3)	48/71 (67.6)	53/71 (74.6)
Switch to ADA	3/125 (2.4)	49/124 (39.5)	62/120 (51.7)	68/118 (57.6)	73/115 (63.5)	67/113 (59.3)
ACR50						
Switch to UPA	2/77 (2.6)	18/77 (23.4)	26/73 (35.6)	26/73 (35.6)	31/71 (43.7)	34/69 (49.3)
Switch to ADA	2/125 (1.6)	12/125 (9.6)	23/123 (18.7)	33/120 (27.5)	29/115 (25.2)	29/112 (25.9)
ACR70						
Switch to UPA	0/77 (0)	5/77 (6.5)	10/75 (13.3)	13/74 (17.6)	15/70 (21.4)	17/72 (23.6)
Switch to ADA	1/125 (0.8)	3/125 (2.4)	7/123 (5.7)	10/120 (8.3)	13/117 (11.1)	14/114 (12.3)
B. Incomplete-responders						
ACR20						
Switch to UPA	60/80 (75.0)	73/78 (93.6)	67/77 (87.0)	67/77 (87.0)	68/77 (88.3)	65/75 (86.7)
Switch to ADA	93/122 (76.2)	98/124 (79.0)	94/119 (79.0)	94/119 (79.0)	87/118 (73.7)	92/119 (77.3)
ACR50						
Switch to UPA	29/80 (36.3)	48/78 (61.5)	50/75 (66.7)	50/75 (66.7)	51/76 (67.1)	45/72 (62.5)
Switch to ADA	38/121 (31.4)	46/122 (37.7)	52/118 (44.1)	52/118 (44.1)	56/119 (47.1)	56/120 (46.7)
ACR70						
Switch to UPA	2/80 (2.5)	19/79 (24.1)	23/76 (30.3)	23/76 (30.3)	27/76 (35.5)	29/74 (39.2)
Switch to ADA	9/123 (7.3)	20/124 (16.1)	20/122 (16.4)	20/122 (16.4)	22/120 (18.3)	22/119 (18.5)

Abbreviations: ACR20/50/70, improvement of ≥20%/50%/70% in American College of Rheumatology criteria; ADA, adalimumab; UPA, upadacitinib.

Supplemental Table S7. Data Points Plotted in Figure 3

	Weeks Post Switch					
Parameter, n/N (%)	0	4	8	12	18	24
A. Non-responders						
CDAI LDA						
Switch to UPA	7/74 (9.5)	22/74 (29.7)	22/70 (31.4)	24/72 (33.3)	29/70 (41.4)	33/70 (47.1)
Switch to ADA	9/124 (7.3)	14/124 (11.3)	26/121 (21.5)	33/120 (27.5)	36/111 (32.4)	41/114 (36.0)
CDAI Remission						
Switch to UPA	1/74 (1.4)	2/74 (2.7)	5/70 (7.1)	6/72 (8.3)	9/70 (12.9)	10/70 (14.3)
Switch to ADA	1/124 (0.8)	1/124 (0.8)	2/121 (1.7)	5/120 (4.2)	5/111 (4.5)	6/114 (5.3)
DAS28(CRP) ≤3.2						
Switch to UPA	8/74 (10.8)	26/74 (35.1)	33/73 (45.2)	31/74 (41.9)	33/70 (47.1)	38/70 (54.3)
Switch to ADA	14/121 (11.6)	20/123 (16.3)	31/121 (25.6)	30/119 (25.2)	34/112 (30.4)	38/109 (34.9)
DAS28(CRP) <2.6						
Switch to UPA	3/74 (4.1)	15/74 (20.3)	19/73 (26.0)	19/74 (25.7)	19/70 (27.1)	22/70 (31.4)
Switch to ADA	5/121 (4.1)	11/123 (8.9)	13/121 (10.7)	15/119 (12.6)	15/112 (13.4)	21/109 (19.3)
B. Incomplete-responders						
CDAI LDA						
Switch to UPA	5/82 (6.1)	40/80 (50.0)	34/76 (44.7)	34/76 (44.7)	42/76 (55.3)	44/76 (57.9)
Switch to ADA	9/126 (7.1)	44/125 (35.2)	41/122 (33.6)	41/122 (33.6)	49/119 (41.2)	54/120 (45.0)
CDAI Remission						
Switch to UPA	0/82 (0)	6/80 (7.5)	7/76 (9.2)	7/76 (9.2)	16/76 (21.1)	12/76 (15.8)
Switch to ADA	0/126 (0)	4/125 (3.2)	3/122 (2.5)	3/122 (2.5)	5/119 (4.2)	6/120 (5.0)
DAS28(CRP) ≤3.2						
Switch to UPA	10/82 (12.2)	46/79 (58.2)	46/76 (60.5)	46/76 (60.5)	48/78 (61.5)	44/77 (57.1)
Switch to ADA	28/126 (22.2)	48/120 (40.0)	41/114 (36.0)	41/114 (36.0)	45/118 (38.1)	53/121 (43.8)
DAS28(CRP) <2.6						
Switch to UPA	3/82 (3.7)	26/79 (32.9)	26/76 (34.2)	26/76 (34.2)	34/78 (43.6)	29/77 (37.7)
Switch to ADA	6/126 (4.8)	17/120 (14.2)	19/114 (16.7)	19/114 (16.7)	22/118 (18.6)	28/121 (23.1)

Abbreviations: ADA, adalimumab; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; LDA, low disease activity; UPA, upadacitinib.

Supplementary Material References

1. Jensen Hansen IM, Asmussen Andreasen R, van Bui Hansen MN, Emamifar A. The reliability of disease activity score in 28 joint-C-reactive protein might be overestimated in a subgroup of rheumatoid arthritis patients, when the score is solely based on subjective parameters: a cross-sectional, exploratory study. *J Clin Rheumatol*. 2017;23(2):102-106.